Financial hardship and cost-related nonadherence to medication in patients with liver disease in the United States.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
revised:
05
05
2024
received:
10
04
2024
accepted:
04
06
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
12
6
2024
Statut:
aheadofprint
Résumé
Economic hardship associated with chronic liver disease (CLD) may delay timely access to healthcare. To estimate the national burden of financial hardship across the spectrum of CLD in the United States (US) during the coronavirus disease 2019 (COVID-19) pandemic. A cross-sectional analysis was performed using the 2020-2021 US National Health Interview Survey database. The questionnaire defined financial hardship from medical bills and cost-related nonadherence to medications in patients with CLD. We used weighted survey analysis to obtain the national estimates. While 6.9% (95% confidence interval [CI]: 6.7%-7.2%) out of 60,689 US adults (weighted sample: 251 million) reported financial hardship and inability to pay medical bills; 10.6% (95% CI: 8.3%-13.4%), 18.2% (95% CI: 14.5%-22.6%), 22.6% (95% CI: 11.0%-41.0%) with hepatitis, CLD/cirrhosis, and liver cancer experienced an inability to pay their medical bills due to financial hardship, respectively. 19.8% (95% CI: 15.9%-24.5%) and 23.3% (95% CI: 12.5%-39.3%) with CLD/cirrhosis and liver cancer, respectively experienced cost-related nonadherence to medications, compared to a tenth of US adults (10.7%, 95% CI: 10.3%-11.2%). CLD/cirrhosis demonstrated an independent association with financial hardship from medical bills and cost-related nonadherence to medications. Overall, these disparities were more pronounced in individuals aged <65 years old. In addition, over 40% of individuals with CLD/cirrhosis reported difficulties accessing medical care during the COVID-19 pandemic. CLD/cirrhosis showed an independent association with difficulties accessing medical care due to COVID-19. Financial hardship from medical bills and cost-related nonadherence to medication can negatively impact individuals with CLD and need further evaluation.
Sections du résumé
BACKGROUND
BACKGROUND
Economic hardship associated with chronic liver disease (CLD) may delay timely access to healthcare.
AIM
OBJECTIVE
To estimate the national burden of financial hardship across the spectrum of CLD in the United States (US) during the coronavirus disease 2019 (COVID-19) pandemic.
METHODS
METHODS
A cross-sectional analysis was performed using the 2020-2021 US National Health Interview Survey database. The questionnaire defined financial hardship from medical bills and cost-related nonadherence to medications in patients with CLD. We used weighted survey analysis to obtain the national estimates.
RESULTS
RESULTS
While 6.9% (95% confidence interval [CI]: 6.7%-7.2%) out of 60,689 US adults (weighted sample: 251 million) reported financial hardship and inability to pay medical bills; 10.6% (95% CI: 8.3%-13.4%), 18.2% (95% CI: 14.5%-22.6%), 22.6% (95% CI: 11.0%-41.0%) with hepatitis, CLD/cirrhosis, and liver cancer experienced an inability to pay their medical bills due to financial hardship, respectively. 19.8% (95% CI: 15.9%-24.5%) and 23.3% (95% CI: 12.5%-39.3%) with CLD/cirrhosis and liver cancer, respectively experienced cost-related nonadherence to medications, compared to a tenth of US adults (10.7%, 95% CI: 10.3%-11.2%). CLD/cirrhosis demonstrated an independent association with financial hardship from medical bills and cost-related nonadherence to medications. Overall, these disparities were more pronounced in individuals aged <65 years old. In addition, over 40% of individuals with CLD/cirrhosis reported difficulties accessing medical care during the COVID-19 pandemic. CLD/cirrhosis showed an independent association with difficulties accessing medical care due to COVID-19.
CONCLUSIONS
CONCLUSIONS
Financial hardship from medical bills and cost-related nonadherence to medication can negatively impact individuals with CLD and need further evaluation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Kim D, Li AA, Gadiparthi C, Khan MA, Cholankeril G, Glenn JS, et al. Changing trends in etiology‐based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology. 2018;155(4):1154–1163. e1153.
GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–266.
Kim D, Perumpail BJ, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A. Changing trends in aetiology‐based hospitalizations with end‐stage liver disease in the United States from 2016 to 2019. Liver Int. 2022;42(11):2390–2395.
Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, et al. Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014. Liver Int. 2019;39(9):1661–1671.
WHO. WHO Coronavirus (COVID‐19) Dashboard. [cited 2023 Feb 1] https://covid19.who.int/
Kim D, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A. Trends in etiology‐based mortality from chronic liver disease before and during COVID‐19 pandemic in the United States. Clin Gastroenterol Hepatol. 2022;20(10):2307–2316. e2303.
Lago‐Hernandez C, Nguyen NH, Khera R, Loomba R, Asrani SK, Singh S. Financial hardship from medical bills among adults with chronic liver diseases: national estimates from the United States. Hepatology. 2021;74(3):1509–1522.
Khera R, Valero‐Elizondo J, Das SR, Virani SS, Kash BA, de Lemos JA, et al. Cost‐related medication nonadherence in adults with atherosclerotic cardiovascular disease in the United States, 2013 to 2017. Circulation. 2019;140(25):2067–2075.
Taha MB, Valero‐Elizondo J, Yahya T, Caraballo C, Khera R, Patel KV, et al. Cost‐related medication nonadherence in adults with diabetes in the United States: the National Health Interview Survey 2013‐2018. Diabetes Care. 2022;45(3):594–603.
Ufere NN, Satapathy N, Philpotts L, Lai JC, Serper M. Financial burden in adults with chronic liver disease: a scoping review. Liver Transpl. 2022;28(12):1920–1935.
Centers for Disease Control and Prevention, NHIS Data, Questionnaires and Related Documentation. [cited 2023 Feb 1]. Available from: https://www.cdc.gov/nchs/nhis/data‐questionnaires‐documentation.htm
Ayyala‐Somayajula D, Dodge JL, Farias A, Terrault N, Lee BP. Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States. J Hepatol. 2023;79(2):329–339.
Kanwal F, Tapper EB, Ho C, Asrani SK, Ovchinsky N, Poterucha J, et al. Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019;69(4):1787–1797.
Shaikh A, Goli K, Lee TH, Rich NE, Benhammou JN, Keeling S, et al. Reduction in racial and ethnic disparity in survival following liver transplant for hepatocellular carcinoma in the direct‐acting antiviral era. Clin Gastroenterol Hepatol. 2023;21(9):2288–2297.
Sempokuya T, Warner J, Azawi M, Nogimura A, Wong LL. Current status of disparity in liver disease. World J Hepatol. 2022;14(11):1940–1952.